Teva Pharmaceutical Industries Ltd. and Active Biotech AB said that testing of 1.2 mg and 1.5 mg doses of the experimental multiple sclerosis (MS) therapy laquinimod have been discontinued in two ongoing studies of the drug after eight patients experienced non-fatal cardiovascular (CV) events.